Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress ...(centage of subjects achieving a weight l...),Health

Results from these studies are expected in the third quarter of 2009.

About EQUATE

The EQUATE study included 756 obese patients (599 females and 157 males) across 32 centers in the United States. The average baseline BMI of the study population was 36.3 kg/m2 and baseline weight was 101.3 kg. The study was a randomized, double-blind, placebo-controlled, prospective trial with subjects randomized to receive once-a-day treatment with mid-dose Qnexa (7.5 mg phentermine/46 mg topiramate CR), full-dose Qnexa (15 mg phentermine/92 mg topiramate CR), the respective phentermine and controlled-release topiramate constituents, or placebo. Patients had a four-week dose titration period followed by 24 weeks of treatment. Subjects were asked to follow a hypocaloric diet representing a 500-calorie/day deficit and advised to implement a simple lifestyle modification program.

About Obesity

More than 300 million people worldwide and approximately 30 percent of American adults (more than 60 million people) are obese, a chronic condition defined by having excess body fat. As the second leading cause of preventable death, obesity directly contributes to numerous life-threatening conditions including diabetes, cardiovascular disease, hypertension and stroke. Experts agree that even a modest weight loss of five percent of weight, maintained over time, can bring significant health benefits by lowering blood pressure and reducing the risk of diabetes and heart disease.

About Qnexa(TM)

Qnexa (Q-NEX-uh) is a proprietary, low dose, controlled release formulation of phentermine and topiramate that simultaneously addresses both appetite and satiety - the two main mechanisms that impact eatin
'/>"/>